PharmacoEconomics

Pharmacoeconomic Evaluation in the Real World: Effectiveness Versus Efficacy Studies
pp. 423-434(12)
Authors: Revicki D.A.; Frank L.

Prescribing at the Interface Between Primary and Secondary Care in the UK: Towards Joint Formularies?
pp. 435-443(9)
Authors: Duerden M.; Walley T.

Counting the Costs of Drug-Related Adverse Events
pp. 445-458(14)
Authors: White T.J.; Arakelian A.; Rho J.P.

The Revised Canadian Guidelines for the Economic Evaluation of Pharmaceuticals
pp. 459-468(10)
Authors: Glennie J.L.; Torrance G.W.; Baladi J.F.; Berka C.; Hubbard E.; Menon D.; Otten N.; Riviére M.

Clinical and Economic Outcomes of Olanzapine Compared With Haloperidol for Schizophrenia: Results From a Randomised Clinical Trial
pp. 469-480(12)
Authors: Hamilton S.H.; Revicki D.A.; Edgell E.T.; Genduso L.A.; Tollefson G.

Reconciling Decision Models With the Real World: An Application to Anaemia of Renal Failure
pp. 481-493(13)
Authors: Shih Y-C.T.; Kauf T.L.

Medical Resource Use and Cost of Venlafaxine or Tricyclic Antidepressant Therapy: Following Selective Serotonin Reuptake Inhibitor Therapy for Depression
pp. 495-505(11)
Authors: Griffiths R.I.; Sullivan E.M.; Frank R.G.; Strauss M.J.; Herbert R.J.; Clouse J.; Goldman H.H.

Direct Costs of Hip Fractures in Patients Over 60 Years of Age in Belgium
pp. 507-514(8)
Authors: Reginster J-Y.; Gillet P.; Sedrine W.B.; Brands G.; Ethgen O.; defroidmont C.; Gosset C.